{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemoradiation", "query": { "condition": "Chemoradiation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 532, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemoradiation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T23:46:50.575Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04391049", "title": "Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma", "Squamous Cell Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Telomerase-specific Type 5 Adenovirus OBP-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-12-02", "completion_date": "2026-10-01", "has_results": true, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 17, "location_summary": "Duarte, California • South Pasadena, California • Upland, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04391049" }, { "nct_id": "NCT01560949", "title": "Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2012-06-14", "completion_date": "2019-02-20", "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01560949" }, { "nct_id": "NCT01536782", "title": "Optimal Tube Feeding Method in Head and Neck Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Bolus", "type": "PROCEDURE" }, { "name": "Gravity", "type": "PROCEDURE" }, { "name": "Pump", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DEVICE" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-02", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01536782" }, { "nct_id": "NCT03021668", "title": "Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Surgical Site Infection", "Pancreatic Neoplasms", "Pancreatic Cancer", "Chemotherapy Effects", "Chemoradiation", "Surgical Wound", "Wound Complication" ], "interventions": [ { "name": "Prevena Peel & Place Dressing", "type": "DEVICE" }, { "name": "Standard Closure of the Surgical Incision", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2017-01", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03021668" }, { "nct_id": "NCT01262560", "title": "Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dysphagia", "Lung Cancer", "Pain", "Esophagitis" ], "interventions": [ { "name": "Manuka honey in liquid form", "type": "DRUG" }, { "name": "Manuka honey in lozenge form", "type": "DRUG" }, { "name": "Standard supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2012-02", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2017-08-31", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 59, "location_summary": "Mobile, Alabama • San Francisco, California • Stanford, California + 50 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262560" }, { "nct_id": "NCT02716896", "title": "Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "Radiation and chemoradiation", "type": "RADIATION" }, { "name": "Radical cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 2, "start_date": "2016-05", "completion_date": "2018-03-26", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02716896" }, { "nct_id": "NCT01133678", "title": "Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 50, "start_date": "2010-05-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2020-05-08", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 2, "location_summary": "Chicago, Illinois • Evanston, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133678" }, { "nct_id": "NCT01847326", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Tongue Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "hyperfractionated radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-03-26", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847326" }, { "nct_id": "NCT07361497", "title": "A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 850, "start_date": "2026-03-16", "completion_date": "2033-12-31", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 38, "location_summary": "Daphne, Alabama • Chandler, Arizona • Golden, Colorado + 32 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Golden", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07361497" }, { "nct_id": "NCT05156060", "title": "Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Locally Advanced Head and Neck Carcinoma" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Natalie Lockney", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 64, "start_date": "2022-01-24", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-06-10T23:46:50.575Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156060" } ] }